Sign in

CIK 0001422143

  • Non-accelerated filer
  • Smaller reporting company

Kura Oncology, Inc.

Sign in to watch
Ticker
KURA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
611547851
Phone
+1 858-500-8800
Business address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
Former names
ZETA ACQUISITION CORP III
  1. 4 Planned sale Chief Commercial Officer sold 10,000 shares at $11.00 ($110,000)
  2. 4 Planned sale Chief Commercial Officer sold 339 shares at $9.21 ($3,122)
  3. 4 Planned sale Chief Operating Officer sold 2,257 shares at $9.08 ($20,483)
  4. 4 Planned sale Chief Legal Officer sold 2,256 shares at $9.38 ($21,160)
  5. 4 Option exercise President and CEO acquired 6,103 shares (option exercise)
  6. 4 Option exercise Director acquired 10,000 shares (option exercise)
  7. 4 Open-market sale Chief Commercial Officer sold 6,414 shares at an average $8.46 ($54,266)
  8. 4 Open-market sale Chief Operating Officer sold 1,813 shares at $8.46 ($15,339)
  9. 4 Open-market sale Chief Medical Officer sold 8,180 shares at $8.46 ($69,209)
  10. 4 Open-market sale SVP, Finance & Accounting sold 7,142 shares at $8.46 ($60,426)
  11. 4 Open-market sale Chief Scientific Officer sold 1,311 shares at $8.46 ($11,092)
  12. 4 Open-market sale Chief Legal Officer sold 11,208 shares at $8.46 ($94,828)
  13. 4 Derivatives Options or other derivatives
  14. 4 Grant or award Chief Medical Officer acquired 50,000 shares (grant or award)
  15. 4 Grant or award SVP, Finance & Accounting acquired 21,250 shares (grant or award)
  16. 4 Grant or award Chief Operating Officer acquired 50,000 shares (grant or award)
  17. 4 Derivatives Options or other derivatives
  18. 4 Grant or award Chief Commercial Officer acquired 50,000 shares (grant or award)
  19. 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
  20. 4 Open-market sale Chief Scientific Officer sold 23,726 shares at $9.78 ($231,931)

Page 2 of 14 · 275 filings